Clinical Risk Resurfaces

Investors focus on the uncertainties around oral obesity mechanisms, including tolerability, dosing, adherence, and whether the pill can match injectable GLP-1 efficacy. The deal adds optionality, but future clinical data remain the decisive catalyst.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.